Idiopathic Pulmonary Fibrosis
Patients with IPF report greater fatigue, shortness of breath after hospitalization
BOSTON — Fatigue and shortness of breath among patients with idiopathic pulmonary fibrosis got worse after being hospitalized, according to data presented at the CHEST Annual Meeting.
Positive topline data reported in phase 3 trial of nerandomilast in adults with IPF
Adults with idiopathic pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-IPF topline results.
Yankees legend Bernie Williams pays tribute to ‘superhero’ dad with ILD initiative
Former New York Yankees center fielder Bernie Williams is sharing resources for patients with interstitial lung disease as a tribute to his late father, who lost his battle with idiopathic pulmonary fibrosis in 2001.
Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of August 12, 2024
In this edition, low education level raises follow-up risk in screening program, screening judgement strongly influenced by clinicians and more.
IPF-related mortality rates differ based on urban, rural areas
Individuals living in medium/small metropolitan and rural areas had increased idiopathic pulmonary fibrosis-related mortality rates vs. those living in large metropolitan areas, according to results published in CHEST.
Deprivation, far hospital distance raise mortality risk in IPF
The risk for mortality was heightened among patients with idiopathic pulmonary fibrosis who experienced more deprivation and lived far from a hospital, according to results published in Respiratory Medicine.
Chemotherapy plus nintedanib has ‘promising’ efficacy in small cell lung cancer with IPF
In a study of patients with small cell lung cancer and idiopathic pulmonary fibrosis receiving carboplatin, etoposide and nintedanib, the primary endpoint was met, according to results published in Annals of the American Thoracic Society.
Top news from ATS 2024 International Conference: IPF treatments, asthma therapies
Doctors from across the world gathered at this year’s American Thoracic Society International Conference in San Diego to present research on various respiratory diseases and conditions.
COPD, IPF end of life health care use differs from lung cancer
SAN DIEGO — Six months before dying, patients with COPD and idiopathic pulmonary fibrosis vs. lung cancer had reduced odds for outpatient palliative care, according to a poster at the American Thoracic Society International Conference.
Bexotegrast safe, well tolerated in IPF for 12 weeks
Among patients with idiopathic pulmonary fibrosis, 12-week bexotegrast was deemed well tolerated and may have an antifibrotic effect, according to results published in American Journal of Respiratory and Critical Care Medicine.